drugset / Trial / NCT01758471

Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes

NCT01758471

RandomizedParallel-groupOpen-labelBasic science

Summary

This study is aimed to investigate the effect of acarbose on intestinal microbiome and incretins, therefore to explore the new pathways or new targets to treat type 2 diabetes.

Timeline

Start
2012-12
Primary completion
2013-12
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown 100 mg Oral
Subject Acarbose Unknown 150 mg Oral
Comparator Glipizide Small molecule 5 mg Oral